Vaxart logo
Vaxart VXRT

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Vaxart Balance Sheet 2011-2025 | VXRT

Annual Balance Sheet Vaxart

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-14.7 M -22.3 M -131 M -125 M -11.2 M -7.9 M -17.4 M -49 M -43.7 M -81.7 M -66.8 M - -94.3 M

Long Term Debt

17.4 M 19.5 M 12 M - - 1.94 M 100 K 300 K 800 K - - - -

Long Term Debt Current

2.7 M 2.23 M 1.01 M 2.05 M 841 K - - - - - - - -

Total Non Current Liabilities

- - - 109 K 14.9 M 16.5 M 15.5 M 17.3 M 900 K 200 K 200 K - 32.8 M

Total Current Liabilities

13.7 M 17.9 M 10.8 M 11.8 M 9.17 M 7.48 M 5.9 M 9.2 M 9 M 26.9 M 15.9 M - 6.25 M

Total Liabilities

34 M 43.2 M 33.6 M 29.2 M 24.1 M 24 M 21.4 M 26.5 M 9.9 M 27.1 M 16.1 M - 39.1 M

Deferred Revenue

- 2 M - - - - - - - - 300 K - 2.53 M

Retained Earnings

-410 M -327 M -219 M - -117 M -98 M -164 M -134 M -109 M -89.8 M -78.6 M - -228 M

Total Assets

91.8 M 154 M 221 M 153 M 37 M 35.2 M 40.1 M 72.7 M 79.4 M 114 M 84.3 M - 98 M

Cash and Cash Equivalents

34.8 M 44 M 144 M 66.9 M 13.5 M 11.5 M 17.7 M 49.7 M 44.7 M 81.7 M 66.8 M 53.8 M 94.3 M

Book Value

57.8 M 111 M 188 M 123 M 13 M 11.2 M 18.7 M 46.2 M 69.5 M 86.9 M 68.2 M - 58.9 M

Total Shareholders Equity

57.8 M 111 M 188 M 123 M 13 M 11.2 M -38.7 M 46.2 M 69.5 M 86.9 M 68 M 59.3 M 58.9 M

All numbers in USD currency

Quarterly Balance Sheet Vaxart

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

11.7 M 12.6 M 13.6 M 14.4 M 15.3 M 16 M 16.7 M 17.4 M 17.9 M 18.6 M 19.2 M 19.5 M - 11.6 M 11.8 M 12 M 11.4 M 4.36 M 4.63 M 5.16 M 5.16 M 5.16 M 5.16 M 1.47 M 1.47 M 1.47 M 1.47 M 17.7 M 17.6 M 17.1 M 16.6 M 15.9 M 16.3 M 16.3 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 296 K 275 K - 504 K - - - - -

Total Liabilities

182 M 131 M 113 M 107 M 98.2 M 33.7 M 33 M 34 M 34.1 M 37.6 M 40.1 M 43.2 M - 38.4 M 34 M 33.6 M 36.2 M 29.1 M 29.6 M 29.2 M 29.2 M 29.2 M 29.2 M 24.1 M 24.1 M 24.1 M 24.1 M 24 M 24 M 24 M 24 M 43.2 M 43.2 M 43.2 M 43.2 M 28.5 M 26.5 M 26.5 M 26.5 M 6.7 M 7.5 M 9.9 M 9.9 M 11 M 19.4 M 27.1 M 27.1 M 18.5 M 14.1 M 17.8 M 16.1 M 17.2 M 36.5 M 10 M 35.8 M 39.1 M 43.4 M 39.1 M 39.1 M

Deferred Revenue

- - - - - - - - 79 K 275 K 1.6 M 2 M - - - - - - - - - - - - 110 K - - 3.33 M 3.28 M 3.15 M 2.04 M 1.2 M 1.5 M 1.4 M 1.4 M 1.2 M 1.2 M 1.3 M 1.3 M - - - - - - - - - 100 K 300 K 300 K 881 K 2.53 M 398 K 2.53 M 2.53 M 2.53 M 2.53 M 2.53 M

Retained Earnings

-515 M -507 M -492 M -477 M -465 M -450 M -434 M -410 M -392 M -375 M -352 M -327 M - -274 M -244 M -219 M -199 M -181 M -165 M -149 M -149 M -149 M -149 M -117 M -117 M -117 M -117 M -98 M -98 M -98 M -98 M -80 M -80 M -80 M -80 M -153 M -144 M -134 M -134 M -122 M -116 M -109 M -109 M -90.2 M -96.7 M -89.8 M -89.8 M -82.8 M -82.5 M -78.8 M -78.6 M -72.3 M -235 M -69.9 M -229 M -228 M -226 M -228 M -228 M

Total Assets

209 M 164 M 159 M 166 M 167 M 114 M 88.7 M 91.8 M 106 M 123 M 130 M 154 M - 181 M 200 M 221 M 241 M 229 M 206 M 153 M 153 M 153 M 153 M 37 M 37 M 37 M 37 M 35.2 M 35.2 M 35.2 M 35.2 M 4.52 M 4.52 M 4.52 M 4.52 M 56.5 M 63.1 M 72.7 M 72.7 M 64.2 M 71 M 79.4 M 79.4 M 93.4 M 97.3 M 114 M 114 M 82.7 M 79 M 85.8 M 84.3 M 96.2 M 66.5 M 69.3 M 95.2 M 98 M 104 M 98 M 98 M

Cash and Cash Equivalents

16.9 M 20.1 M 28.7 M 25.2 M 22 M 43.3 M 26.7 M 34.8 M 33.2 M 43.3 M 46.8 M 46 M 50.8 M 91.5 M 123 M 144 M 167 M 165 M 157 M 127 M 33.4 M 44.4 M 29.9 M 13.5 M 19.6 M 16.3 M 8.4 M 11.5 M 17.9 M 23.9 M 17.5 M 1.57 M 1.57 M 29.4 M 1.57 M 8.4 M 45.9 M 38.1 M 45.9 M 39 M 45.3 M 39 M 45.3 M 63.7 M 57.7 M 63.7 M 57.7 M 51.4 M 60.8 M 51.4 M 60.8 M 74.1 M 47.1 M 74.1 M 53.3 M 57.5 M 94.3 M 94.3 M 94.3 M

Book Value

26.8 M 32.9 M 45.6 M 58.9 M 68.4 M 80 M 55.7 M 57.8 M 71.5 M 85.1 M 89.8 M 111 M - 143 M 166 M 188 M 205 M 200 M 176 M 123 M 123 M 123 M 123 M 13 M 13 M 13 M 13 M 11.2 M 11.2 M 11.2 M 11.2 M -38.7 M -38.7 M -38.7 M -38.7 M 28 M 36.6 M 46.2 M 46.2 M 57.5 M 63.5 M 69.5 M 69.5 M 82.4 M 77.9 M 86.9 M 86.9 M 64.2 M 64.9 M 68 M 68.2 M 79 M 30 M 59.3 M 59.4 M 58.9 M 60.7 M 58.9 M 58.9 M

Total Shareholders Equity

26.8 M 32.9 M 45.6 M 58.9 M 68.4 M 80 M 55.7 M 57.8 M 71.5 M 85.1 M 89.8 M 111 M 122 M 143 M 166 M 188 M 205 M 200 M 176 M 123 M 123 M 123 M 123 M 13 M 13 M 13 M 13 M 11.2 M 11.2 M 11.2 M 11.2 M -38.7 M -38.7 M -38.7 M -38.7 M -29.6 M 36.6 M 28 M 46.2 M 57.5 M 63.5 M 69.5 M 69.5 M 82.4 M 77.9 M 86.9 M 86.9 M 64.2 M 64.9 M 68 M 68.2 M 79 M 30 M 59.3 M 59.4 M 67.4 M 58.9 M 58.9 M 58.9 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Vaxart, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 17.91 -1.0 % $ 7.59 B niderlandNiderland
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.09 -4.82 % $ 152 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aptorum Group Limited Aptorum Group Limited
APM
$ 1.15 -1.71 % $ 6.27 M chinaChina
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.78 -0.31 % $ 793 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.03 -0.49 % $ 234 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 209.39 -1.61 % $ 5 B danmarkDanmark
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
$ 0.6 -35.8 % $ 166 K usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.66 -1.49 % $ 424 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.12 0.81 % $ 7.51 B australiaAustralia
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioVie BioVie
BIVI
$ 1.2 -5.51 % $ 1.77 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 0.22 24.46 % $ 479 M israelIsrael
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 94.72 -0.33 % $ 27.2 B germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 27.09 1.04 % $ 1.31 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 9.6 1.27 % $ 141 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 18.4 -0.97 % $ 18.2 B chinaChina
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.33 -0.29 % $ 812 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 584.81 -1.07 % $ 44.3 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.44 -3.56 % $ 15.3 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 92.79 0.37 % $ 96.9 B britainBritain
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Certara Certara
CERT
$ 8.9 -0.17 % $ 1.43 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA